Cloudbyz

APRIL 10, 2023

Chronic diseases such as heart disease, diabetes, cancer, and respiratory diseases are major health concerns that can significantly impact an individual’s quality of life. This not only reduces air pollution but also promotes physical activity, which is essential for overall health.

Production 52

Production Clinical Research Development Research 52

The Pharma Data

JUNE 2, 2023

“These additional data on Verzenio and Jaypirca build on the evidence supporting the role each of these medicines play in improving the treatment paradigms for patients with node-positive, high risk early breast cancer and covalent BTK inhibitor pre-treated relapsed or refractory MCL, respectively,” said David Hyman, M.D.,

HR 52

HR Hormones Medicine Trials 52

Drug Discovery World

AUGUST 14, 2023

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. The European Commission (EC) granted marketing authorisation for Akeega in April 2023.

FDA Approval 52

FDA Approval Gene Drugs Marketing 52

pharmaphorum

NOVEMBER 18, 2021

The FDA gave EaseVRx breakthrough status last year, recognising its potential in reducing the reliance of people with chronic lower back pain on painkiller medications – with the accompanied risk of dependency and side effects – and the difficulties in accessing face-to-face physiotherapy and CBT sessions that have been exacerbated by the pandemic.

Clinical Trials 98

Clinical Trials Clinical Trials Production Development 98

pharmaphorum

SEPTEMBER 16, 2022

The positive readout from the CheckMate-76K study means that Opdivo (nivolumab) has a chance to draw level again with Merck & Co’s rival cancer immunotherapy Keytruda (pembrolizumab), which was approved for adjuvant treatment of melanoma last December.

FDA Approval 98

FDA Approval Trials Drugs Development 98

Drug Discovery World

DECEMBER 14, 2023

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. MBRC-101 targets the EphA5 receptor tyrosine kinase, which is present in multiple cancers, including breast, non-small cell lung (NSCLC), colorectal, gastric and pancreatic cancers.

HR 52

HR Hormones Trials In-Vivo 52

pharmaphorum

DECEMBER 21, 2022

AstraZeneca and Daiichi Sankyo’s Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available via the Cancer Drugs Fund. The post NICE expands breast cancer patient population eligible for Enhertu appeared first on.

Drugs 64

Drugs Clinical Trials Clinical Trials Antibody 64

pharmaphorum

DECEMBER 22, 2022

Loder stated that well over half of investment dollars are spent on cancer. Ultimately, she said, the majority of cancer diagnoses need to be carried out much earlier on. She also mentioned, “vaccines before cancer even presents, before the massively hostile tumour environment”. Reimbursement and diagnostics markers.

Clinical Trials 98

Clinical Trials Clinical Trials Vaccination Vaccine 98

Drug Discovery World

SEPTEMBER 26, 2023

In addition to providing the latest statistics on cancer incidence, mortality, and survivorship, the AACR Cancer Progress Report 2023 offers detailed updates and important context regarding the latest research in cancer etiology, early detection, diagnosis, treatment, prevention, and survivorship. million cancer deaths avoided.

Research 52

Research Clinical Trials Clinical Trials FDA Approval 52

The Pharma Data

OCTOBER 16, 2020

Use of Common Meds Tied to Lower Lung Cancer Mortality. 16, 2020 — Use of aspirin , metformin , and statins is associated with a lower risk for lung cancer mortality, according to a study published online Sept. Lung cancer mortality was similarly lower in a dose-dependent fashion with the use of aspirin and statins.

Research 52

Research Development Drugs 52

XTalks

FEBRUARY 9, 2023

Leading clinical trials technology platform provider Medable announced a new partnership with Nova Scotia Health Innovation Hub for a two-year pilot study to improve oncology trial access for patients in rural Nova Scotia through Medable’s decentralized clinical trial (DCT) platform. Nova Scotia is Canada’s second smallest province by area.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Clinical Research 98

The Pharma Data

APRIL 12, 2022

20% variant allele frequency reduction – At the time of analysis with > 2 year follow up the survival estimate was 100% in patients who had improvements in bone marrow fibrosis or variant allele frequency – Results were presented at the American Association for Cancer Research annual meeting.

Trials 52

Trials Medicine Protein Clinical Development 52

Roots Analysis

NOVEMBER 5, 2023

Cancer is the second leading cause of death globally, and the increasing global incidence of cancer is becoming a critical health challenge. million cancer related deaths are likely to occur by 2040. According to WHO, approximately 16.3 This personalized approach can lead to more effective and targeted therapies.

Marketing 40

Marketing Genetics DNA Research 40

Pharma in Brief

JANUARY 7, 2024

The stated purpose of the US Importation Rule is “to achieve a significant reduction in the cost of covered products to the American consumer while posing no additional risk to the public’s health and safety.” Biologics, controlled substances, and certain other drugs are not eligible for importation.

Drugs 52

Drugs Regulation FDA Approval Manufacturing 52

pharmaphorum

NOVEMBER 10, 2022

To continue with pharmaphorum’s coverage of Day One of The Economist’s 8th Annual World Cancer Series congress in Brussels, Belgium this week – where the foci were “innovation, equity, and excellence” – after the opening addresses came a panel on the priorities for innovation and excellence in cancer care within Europe.

Nurses 97

Nurses Research Clinical Trials Clinical Trials 97

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 13 People at increased risk of exposure to the SARS-CoV-2 virus could also benefit from protection with Evusheld.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

DECEMBER 9, 2020

9, 2020 — Mindfulness, meditation and survivorship education can help young breast cancer survivors overcome depression and other problems, a new study indicates. About 20% of breast cancer cases occur in women younger than 50, many of whom face significant struggles. WEDNESDAY, Dec. © 2020 HealthDay. © 2020 HealthDay.

Research 52

Research Development 52

The Pharma Data

APRIL 12, 2022

a one-third reduction in “premature” deaths from diseases like diabetes, cancer, heart and lung disease and the promotion of mental health and well-being. billion people living with NCDs and mental health conditions in policy-making and programming. This is also vital for promoting universal health coverage.

Development 52

Development Medicine Production 52

The Pharma Data

MARCH 25, 2022

2 subvariant is rapidly increasing and where public health safety measures have been relaxed in many countries. 14) The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease – a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.(15)

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

pharmaphorum

SEPTEMBER 8, 2022

“A wide range of independent research shows that there is a risk of patients using their injection devices incorrectly,” according to Gulli Arnason, Sidekick’s chief marketing and communications officer. “The collaboration is all about putting patients first,” he told pharmaphorum.

Compliance 105

Compliance Pharma Companies Branding Development 105

pharmaphorum

OCTOBER 26, 2020

Preventive care programmes are key to better health outcomes, but several factors are limiting their uptake. Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases.

Life Science 130

Life Science Genetics Development Vaccination 130

The Pharma Data

AUGUST 12, 2020

In the UK, women aged 50-70 are offered breast screening unless there is a high genetic risk. Screening women for breast cancer from their 40s rather than their 50s could save lives without adding to the diagnosis of harmless cancers, a UK study has found. Image caption. Over-diagnosis fear.

Scientist 52

Scientist Research Doctors Doctor 52

pharmaphorum

MAY 27, 2021

The drug will be sold as Myfembree (relugolix) for the uterine fibroids indication, and is already available to treat prostate cancer under the Orgovyx brand name. billion collaboration to develop the drug in women’s health and oncology in late 2020, including $650 million upfront and $200 million for regulatory milestones.

Hormones 98

Hormones Sales Marketing Drugs 98

The Pharma Data

APRIL 28, 2022

“The proposed rules would help prevent children from becoming the next generation of smokers and help adult smokers quit,” said Health and Human Services Secretary Xavier Becerra. Additionally, the proposed rules represent an important step to advance health equity by significantly reducing tobacco-related health disparities.”.

Production 52

Production Cosmetics Regulation Manufacturing 52

The Pharma Data

MARCH 17, 2022

Merck (NYSE: MRK), known as MSD outside the United States and Canada, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Thoracic Oncology Platform (ETOP) today announced results from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS. Median DFS was 53.6 About EORTC.

Clinical Trials 52

Clinical Trials Clinical Trials Research Trials 52

The Pharma Data

JUNE 7, 2023

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA Moderna, Inc.

Clinical Trials 40

Clinical Trials Clinical Trials HR Medicine 40

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. The improvement in OS increased to a 48 percent reduction in risk of death after adjusting for patients who crossed over (HR 0.52; p<0.0001).

HR 52

HR Hormones Development Production 52

pharmaphorum

MAY 25, 2022

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD’s Keytruda, on the recommendation of cost-effectiveness agency NICE. The post NICE finds solution to making Keytruda available for TNBC appeared first on.

Drugs 64

Drugs Regulation Trials Marketing 64

pharmaphorum

SEPTEMBER 17, 2021

Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide an oral alternative to AstraZeneca’s injectable Faslodex for breast cancer.

HR 52

HR Hormones Trials Sales 52

Drug Discovery World

FEBRUARY 21, 2024

PS : Natural Killer (NK) cells play an essential role in maintaining human health and overall immune integrity. We were also able to show a dose-response reduction in AB42/40, p-Tau levels in cerebrospinal fluid, as well as a reduction in neuroinflammation markers like GFAP (Glial fibrillary acidic protein).

Protein 122

Protein Trials Genetics Antibody 122

XTalks

DECEMBER 4, 2023

Most oncology products approved in the past few decades are known for being highly toxic, non-specific and fraught with severe side effects for cancer patients. This was because higher doses often correlated with a better reduction in tumor size, so trial designs were predicated on obtaining the maximum tolerated dose (MTD).

Development 111

Development Drugs Clinical Trials Clinical Trials 111

XTalks

NOVEMBER 30, 2023

The World Health Organization (WHO) has designated the theme of World AIDS Day 2023 as “Let Communities Lead.” According to the WHO, HIV continues to be a significant global public health concern, claiming the lives of 40.4 percent of patients receiving Sunlenca experienced a significant reduction in virus levels, compared to only 16.7

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. These are particularly important in the progression of certain blood cancers.

Development 52

Development Drugs Clinical Development Antibody 52

pharmaphorum

OCTOBER 9, 2022

UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal.

Insulin 59

Insulin Antibody Regulation Development 59

The Pharma Data

AUGUST 15, 2021

Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the results of a new real-world study that shows its ECHELON CIRCULAR Powered Stapler was associated with a 74% reduction in anastomotic leak rates (1.8% vs. 6.9%) [1] and a 44% reduction in 30-day inpatient hospital readmission rates (6.1%

Clinical Trials 52

Clinical Trials Clinical Trials Branding Trials 52

pharmaphorum

SEPTEMBER 29, 2022

At the moment, treatment typically involves oral or topical corticosteroids, antihistamines, and some antidepressant drugs, but responses are often inadequate, vary widely between patients, and come with the burden of safety risks if used long-term. Here is a patient (*written consent obtained) I saw just 2 weeks ago with severe disease.

Drugs 69

Drugs Immune Response Allergies Sales 69

Delveinsight

AUGUST 17, 2021

A delay in progression of advanced kidney cancer and a 34 % reduction in risk of death was observed in newly advanced kidney cancer diagnosed patients. This approval comes as a second approval for the combination of Keytruda and Lenvima, after having an accelerated approval for endometrial cancer back in 2019.

FDA Approval 98

FDA Approval Medicine Vaccination Vaccine 98